Home > Publications database > C-terminal Modulators of Heat Shock Protein of 90 kDa (HSP90): State of Development and Modes of Action > print

001     864930
005     20210130002800.0
024 7 _ |a 10.1016/j.bmc.2019.115080
|2 doi
024 7 _ |a 0968-0896
|2 ISSN
024 7 _ |a 1464-3391
|2 ISSN
024 7 _ |a 2128/23059
|2 Handle
024 7 _ |a pmid:31519378
|2 pmid
024 7 _ |a WOS:000488203800001
|2 WOS
037 _ _ |a FZJ-2019-04533
082 _ _ |a 610
100 1 _ |a Bickel, David
|0 P:(DE-HGF)0
|b 0
245 _ _ |a C-terminal Modulators of Heat Shock Protein of 90 kDa (HSP90): State of Development and Modes of Action
260 _ _ |a Amsterdam [u.a.]
|c 2019
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1570005676_13644
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cells constantly need to adopt to changing environmental conditions, maintaining homeostasis and proteostasis. Heat shock proteins are a diverse class of molecular chaperones that assist proteins in folding to prevent stress-induced misfolding and aggregation. The heat shock protein of 90 kDa (HSP90) is the most abundant heat shock protein. While basal expression of HSP90 is essential for cell survival, in many tumors elevated HSP90 levels are found, which is often associated with bad prognosis. Therefore, HSP90 has emerged as a major target in tumor therapy. The HSP90 machinery is very complex in that it involves large conformational changes during the chaperoning cycle and a variety of co-chaperones. At the same time, this complexity offers a plethora of possibilities to interfere with HSP90 function. The best characterized class of HSP90 modulators are competitive inhibitors targeting the N-terminal ATP-binding pocket. Nineteen compounds of this class entered clinical trials. However, due to severe adverse effects, including induction of the heat shock response, no N-terminal inhibitor has been approved by the FDA so far. As alternatives, compounds commonly referred to as “C-terminal inhibitors” have been developed, either as natural product-based analogues or by rational design, which employ multiple mechanisms to modulate HSP90 function, including modulation of the interaction with co-chaperones, induction of conformational changes that influence the chaperoning cycle, or inhibition of C-terminal dimerization. In this review, we summarize the current development state of characteristic C-terminal inhibitors, with an emphasis on their (proposed) molecular modes of action and binding sites.
536 _ _ |a 511 - Computational Science and Mathematical Methods (POF3-511)
|0 G:(DE-HGF)POF3-511
|c POF3-511
|f POF III
|x 0
536 _ _ |a Forschergruppe Gohlke (hkf7_20170501)
|0 G:(DE-Juel1)hkf7_20170501
|c hkf7_20170501
|f Forschergruppe Gohlke
|x 1
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Gohlke, Holger
|0 P:(DE-Juel1)172663
|b 1
|e Corresponding author
|u fzj
773 _ _ |a 10.1016/j.bmc.2019.115080
|g p. 115080 -
|0 PERI:(DE-600)1501507-5
|n 21
|p 115080
|t Bioorganic & medicinal chemistry
|v 27
|y 2019
|x 0968-0896
856 4 _ |y Published on 2019-08-26. Available in OpenAccess from 2021-08-26.
|u https://juser.fz-juelich.de/record/864930/files/Hsp90_CT_inhib_review_final.pdf
856 4 _ |y Published on 2019-08-26. Available in OpenAccess from 2021-08-26.
|x pdfa
|u https://juser.fz-juelich.de/record/864930/files/Hsp90_CT_inhib_review_final.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:864930
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)172663
913 1 _ |a DE-HGF
|b Key Technologies
|1 G:(DE-HGF)POF3-510
|0 G:(DE-HGF)POF3-511
|2 G:(DE-HGF)POF3-500
|v Computational Science and Mathematical Methods
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|l Supercomputing & Big Data
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Embargoed OpenAccess
|0 StatID:(DE-HGF)0530
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BIOORGAN MED CHEM : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)JSC-20090406
|k JSC
|l Jülich Supercomputing Center
|x 0
920 1 _ |0 I:(DE-Juel1)NIC-20090406
|k NIC
|l John von Neumann - Institut für Computing
|x 1
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 2
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)JSC-20090406
980 _ _ |a I:(DE-Juel1)NIC-20090406
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
981 _ _ |a I:(DE-Juel1)IBI-7-20200312

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21